- What the results of current studies with enzalutamide say - a commentary on the studies2021 | Publication without faculty affiliation
- Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy2016 | First Faculty of Medicine
- Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy2023 | First Faculty of Medicine
- Docetaxel-Cabazitaxel-Enzalutamide Versus Docetaxel-Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer2017 | First Faculty of Medicine
- Enzalutamide in treatment of the metastatic castrate resistant prostate cancer2019 | First Faculty of Medicine
- Enzalutamide before chemotherapy in the treatment of metastatic castration-resistant prostate2019 | First Faculty of Medicine
- Dlouhodobý efekt léčby enzalutamidem u pacienta s kastračně rezistentním karcinomem prostaty v postchemoindikaci2019 | Publication without faculty affiliation
- Treatment options of non-metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine
- Novel therapeutic options in prostate cancer before chemotherapy2013 | First Faculty of Medicine
- The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide2018 | First Faculty of Medicine
- Enzulutamide in treatment in patients with metastatic castration-resistant prostate cancer after previous chemotherapy2017 | First Faculty of Medicine
- The importance of cooperation between urologist and oncologist in the treatment of castration-resistant prostate cancer2014 | First Faculty of Medicine
- The importance of cooperation between urologist and oncologist in the treatment of castration-resistant2014 | First Faculty of Medicine
- Účinnost enzalutamidu v léčbě metastatického kastračně rezistentního karcinomu prostaty2020 | First Faculty of Medicine
- New treatment options in hormone-sensitive prostate cancer +12019 | First Faculty of Medicine
- Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 1-and 2-Year Open-label Follow-up Results2015 | First Faculty of Medicine
- Current treatment options for metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Medicine in Hradec Králové
- Studie PROSPER - nová indikace "staronového" léku: enzalutamid v léčbě nemetastatického kastračně rezistentního karcinomu prostaty2020 | Third Faculty of Medicine
- Pacient s kastračně rezistentním karcinomem prostaty léčený enzalutamidem v pre-chemo indikaci - klinické zkušenosti2019 | Publication without faculty affiliation
- Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate2024 | Faculty of Medicine in Pilsen
- Prostate cancer - cardiac complications of treatment2021 | First Faculty of Medicine
- Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience2023 | Faculty of Medicine in Pilsen
- New hormonal agents in castration-resistant prostate cancer2013 | First Faculty of Medicine
- Treatment of advanced prostate cancer2016 | First Faculty of Medicine
- Trends in the treatment of metastatic castration-sensitive prostate cancer2023 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Sekvence abirateronu a enzalutamidu v léčbě metastatického kastračně rezistentního karcinomu prostaty2020 | First Faculty of Medicine
- Role of the Urologist in the Treatment of Castration-Resistant Prostate Cancer in the Czech Republic2013 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine
- Možnosti léčby karcinomu prostaty po selhání docetaxelu2015 | First Faculty of Medicine
- Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study2014 | First Faculty of Medicine, Third Faculty of Medicine